Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Direxion Daily Semiconductor Bear 3X Shares trades at $44.48 (market cap $2.44B). The key difference: Dyne Therapeutics Inc. Common Stock is the larger of the two by market cap, and Direxion Daily Semiconductor Bear 3X Shares is more actively traded (88,729,812 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Direxion Daily Semiconductor Bear 3X Shares for 11 Days on average.
| DYN | SOXS | |
|---|---|---|
Market Cap | $2.86B | $2.44B |
Volume | 3,341,579 | 88,729,812 |
Sector | Health | Leveraged / Inverse |
52-Week High | $26.78 | $944.00 |
52-Week Low | $14.60 | $29.62 |
Typical Hold Time | 0 Days | 11 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SOXS trades at $37.42, up 0.48% with a mixed technical outlook showing bullish overall signals but bearish moving averages. The ETF faces significant volatility as a 3x leveraged inverse semiconductor fund, with recent performance driven by semiconductor sector weakness. Recent news highlights ongoing challenges in the semiconductor space, including Nvidia's China exposure and competitive pressures.
As a tactical inverse ETF, SOXS offers short-term hedging potential against semiconductor declines but carries substantial decay risks for long-term holders. The fund's structure makes it unsuitable for buy-and-hold strategies, with success dependent on accurately timing semiconductor sector downturns amid persistent AI demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
